1832 Asset Management’s Novavax NVAX Stock Holding History

1832 Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-140	Closed	-$12K	–	649
2014 Q3	$12K	Buy	+140	New	+$12.7K	﹤0.01%	551

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management's NVAX Position: Q4 2014 in Review

1832 Asset Management sold out of Novavax (NVAX) in Q4 2014, closing a stake of 140 shares — an estimated $12K sold.

1832 Asset Management first reported a position in NVAX in Q3 2014 and held it in 1 quarter. The position peaked at $12K in Q3 2014. 153 funds tracked by Wall St. Rank hold NVAX as of Q4 2014.

1832 Asset Management reported no remaining Novavax position as of Q4 2014 after selling out during the quarter.
1832 Asset Management sold 140 Novavax shares in Q4 2014, an estimated $12K.
1832 Asset Management first reported a position in Novavax in Q3 2014 and held it in 1 quarter.
1832 Asset Management's Novavax position peaked at $12K in Q3 2014.
153 funds tracked by Wall St. Rank held Novavax as of Q4 2014.

Based on 1832 Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.